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Background and Purpose. Dry socket syndrome is one of the most irritating complications after tooth extraction. This study aims
to investigate the eﬃcacy of pastille GECB compared to ZOE. Materials and Methods. 30 patients with dry socket syndrome were
selected and divided into two groups. GECB pastille was produced with 3% Guaiacol, 3% Eugenol 1.6% Chlorobutanol, sized
3 × 7 × 10mm. GECB was applied in one group, and ZOE was used for the other group. Duration of pain after treatment and
painkiller intake values were recorded within 20 days. The data were analyzed with independent samples t-test, Mann-Whitney,
and Chi-Square tests. Results. Pain persisted for 45.53 ± 33.34 minutes in patients treated with ZOE and 19.87 ± 21.80 minutes
in those treated with GECB (P = 0.19). Patients in the ZOE group reported more painkiller intake within 20 days (P = 0.031).
Conclusion. GECB showed more signiﬁcant eﬃcacy in reducing complications after tooth extraction.
1.Introduction
Pain, bleeding, infection, paresthesia, temporomandibular
disorders, abscess formation, and dry socket have been
known as common complications following extraction of
impacted wisdom teeth [1, 2]. Dry socket syndrome was in-
troduced for the ﬁrst time by Crawford. This syndrome is
characterizedby severepain in theextraction andperiextrac-
tion site accompanying by blood clot lysis and halitosis [3].
In Nusair and Abu Younis study, 7.9% was the highest rate of
dry socket syndrome that occurred in the range 18–33 years
old [4]. The occurrence of this syndrome after extraction of
other teeth than third molar is about 2% while the incidence
ofthissyndromeafterthirdmolarextractionis20%[5].Also
in Haghighat study, it was concluded that there is a signiﬁ-
cant correlation between the use of oral contraceptive pills,
traumatic extraction, and smoking cigarette with occurrence
of postoperative dry socket syndrome [6].
Until now, diﬀerent preventive and therapeutic methods
havebeenproposedbasedonmultifactorialandcomplexeti-
ology of dry socket syndrome. Some studies focused on an-
tibiotics and antibacterial agents as an eﬀective way in the
management of dry socket syndrome. In Swanson [1]a n d
Akota et al. [2] studies, the use of antibiotics was shown
eﬀective in the management of the syndrome. Beside anti-
biotics, other studies concentrated on the eﬀect of 12%
chlorhexidinemouthwash,anditwasdeclaredthatthisagent
signiﬁcantly reduces the dry socket syndrome complications
compared to control group [7]. Cai and Lu investigated
the eﬃcacy of Gelatamp colloidal silver gelatin sponge in
prevention of postextraction complications and concluded
that Gelatamp was eﬀective in prevention of dry socket
syndrome [8]. In Keesling and Keats study, zinc oxide
eugenol ointment was compared with placebo, regarding the
dry socket prevention, and it was shown that ZOE is more
eﬀective than placebo [9].2 International Journal of Dentistry
From diﬀerent suggested methods, Guaiacol, Eugenol,
Chlorobutanol, and Balsam peru mixture (G.E.C.B) is a new
material, introduced by Sultan company in the name of
Dentalone. This mixture is a paste, consists of 3% guaiacol,
3% Eugenol, and 1.6% Chlorbutanol as an eﬀective agent
and Balsam peru as a base. According to therapeutic and
alleviative eﬀects of its ingredients, this paste was released by
Sultan chemists in the name of Dry socket paste.
Dry socket syndrome is one of the most painful com-
plications following impacted third molar extraction, and it
canaﬀectbothpatientsandcliniciansemotionallyandﬁnan-
cially.Astherearenodeﬁniteexplanationsfortheoccurrence
of this syndrome and prevention of this syndrome is an
important duty for clinicians, the aim of this study is to
investigate the eﬃcacy of the new form of GECB drug as
pastille in management of dry socket syndrome-related com-
plications.
2.Methods and Materials
2.1. Patient Selection. In this randomized clinical trial, 30
patients aged from 18 to 40 who referred to maxillofacial
surgery department of Isfahan University of medical sciences
and diagnosed with dry socket syndrome after impacted
lower third molar extraction were selected. These patients
consisted of 7.5% of the whole patients. Patients with allergy
to either of the dressing materials used in the study, infection
in the site of tooth extraction and those who refused to
participate in the study, were excluded. Patients who met
the inclusion criteria (pain in the lower arch following tooth
extraction which can refer to ears, exposure of alveolar
bone, and empty alveolar socket) were randomly divided
into two groups. Fifteen patients (11 males and 4 females)
undergonetreatmentwithZOE,andﬁfteenpatients(7males
and 8 females) were treated with pastille GECB. An informed
consent was signed by patients, and the study has been
ethically approved by Isfahan dental school (no. 390053).
2.2. GECB Pastille Preparation. GECB pastille was prepared
according to oﬃcial formula which has been released by Sul-
tan Company and approved by FDA. 3% eugenol (Merck),
3% Guaiacol (Merck), and 1.6% chlorobutanol are the
eﬀectiveingredientsinthepastille.Allmentionedingredients
were inserted in the gelatin pastille formulation containing
gelatin, glycerin, and sugar. After mixing all together, the
mixture was poured in 3 × 7 × 10mm mold. Molds were
allowed to get cool, and then ﬂexible pastilles were ready to
use.
2.3. Medications Application. First, patients’ pain was as-
sessed by visual analog scale (VAS). In the case group,
GECB pastille and in control group ZOE dressing was used.
After pastille and ZOE placement, the elapsed time for the
patient’s pain to signiﬁcantly relieve was recorded. After the
treatment, ibuprofen pills were prescribed as needed (PRN).
Patients were followed for 20 days, and the pain severity
was assessed by VAS, and the number of consumed pills was
Table 1: Comparison of age and VAS-scale of the patients between
the groups.
Criteria Group N Mean Std.
deviation
Std. error
mean
Age ZOE 15 28.80 5.51 1.42
GECB 15 30.93 6.46 1.66
VAS-
scale
ZOE 15 8.33 1.04 0.27
GECB 15 8.27 0.70 0.18
Table 2: Healing time and ibuprofen intake compared between the
two groups.
Criteria Group N Mean Std.
deviation
Std. error
mean
Healing-time ZOE 15 45.53min 33.33 8.60
GECB 15 9.87min 7.62 1.96
Ibuprofen ZOE 15 212mg 0.74 0.19
GECB 15 32mg 0.25 0.06
recorded after this period. Data were analyzed by Mann-
withney and independent sample t-test using SPSS software
versus 15 (α = 0.05).
3. Results
In the present study, 30 patients with mean age of 29.87 ±
6.00 were assessed. The mean age of patients was 28.80 ±
5.52 and 30.93 ± 6.64 in ZOE and GECB group, respectively.
The mean age of patients showed no signiﬁcant diﬀerence
between two groups (P = 0.339).
73% and 47% of the patients were male in ZOE and
GECB groups, respectively. Also there was no signiﬁcant
diﬀerence between two groups regarding their gender (P =
0.136) as illustrated in Table 1.
In the present study, the severity of pain before any
treatment was also assessed by VAS scale in each patient. The
meanscorewas8.33 ±1.05and8.27 ±0.7inZ OEandGECB
groups which showed no signiﬁcant diﬀerence (P = 0.839).
Independent sample t-test revealed that there is a sig-
niﬁcant diﬀerence between two groups in terms of the time
elapsedforthepaintosigniﬁcantlyrevealafterthetreatments
(P = 0.019). In the ZOE and GECB groups, the pain reduced
after 45.53 ± 33.34 and 19.87 ± 21.80 minutes, respectively.
Patients, who received ZOE and GECB treatments, aver-
agelyused0.53 ±0.74and0.07 ±0.26400mgibuprofenpills
during the follow-up period. Mann-Whitney test showed
that there was a signiﬁcant diﬀerence in the number of
consumed pills between the two groups (Table 2).
4. Discussion
Despite the importance of the dry socket syndrome, many
cliniciansarenotwillingtodiscussaboutadeﬁnitetreatment
approach toward this syndrome, as the etiology, and the
treatment of this syndrome is highly controversial [10]. UntilInternational Journal of Dentistry 3
today, symptomatic treatments are the most common way
for pain alleviation. Considering the fact that the pain in dry
socket syndrome will last for 10–15 days regardless of the
treatment method, all the suggested treatment has focused
on the pain reduction [10, 11]. Some researchers believed
that the use of dressing pastes, not only delivers the eﬀective
material to the involved site, but also acts as a barrier for
the socket. It should be emphasized that dressing materials
should not act as a hindrance for wound-healing procedure
and the dressing must be replaced with socket rinsing [12,
13].
In the present study, the mean age of patients showed
no signiﬁcant diﬀerence between the two groups. It is an
important factor to consider, as some studies indicate that
theincidenceofdrysocketsyndromeincreaseswithage[14].
Sotonegatetheeﬀectsof this factorasconfounding variable,
the patients were monitored regarding their age.
Moreover, the primary pain before treatment was not
signiﬁcantly diﬀerent between the two groups which cannot
have any confounding eﬀect on the results of the study.
The pain rate in the GECB group was signiﬁcantly lower,
regarding its duration and the number of required pain
killers. But it should be added that ZOE dressing is an ac-
ceptable treatment [15].
Guaiacol is an eugenol-like phenolic combination [16].
This material, for the ﬁrst time, was used as cement in den-
tistry and also used as an adjunctive treatment for pains with
pulp origin [17, 18]. Also like other phenolic combinations,
guaiacol can induce cellular proliferation, and this feature
limited the use of this material [19]. It is believed that the
alleviative eﬀect of ZOE is due to its eugenol. As Eugenol
is present also in GECB pastille and the eﬀect of GECB is
superiortoZOE,itcanbeconcludedthatthealleviativeeﬀect
of Guaiacol is more than that of Eugenol [20].
One of the major advantages of GECB over traditional
ZEO dressing is its convenience. As the treatment of dry
socket syndrome by ZOE needs dressing replacement each
3 days for 1 week, some researchers consider it as an imped-
iment in the treatment procedure [21]. In the present study,
GECB pastille which is a mixture of medicament in gelatin
and sugar was used. This pastille is a solid, transparent
materialwithpleasanttaste,anditdoesnotneedpreparation
before its use. This signiﬁcantly saves the patients’ time and
is more convenient for them. As the entire ingredients in
the pastille have been approved by F.D.A, the mentioned
pastille also can be approved and released in the market with
diﬀerent concentrations.
Thecomparisonofthepresentstudywithotherstudiesis
challenging as the pastille form of this drug was used for the
ﬁrst time in the treatment of dry socket syndrome. Despite
the conclusive results of the present study, further studies
with bigger sample sizes and diﬀerent concentrations of the
medicament should be conducted.
5. Conclusion
It can be concluded that there is a signiﬁcant diﬀerence in
the capacity of two diﬀerent methods in pain alleviation. It
seems that this eﬀect is mainly due to use of Guaiacol. Also
because of GECB pastille convenience and its one session use
with less chair time, compared to ZOE, it can be an eﬀective
and reliable alternative for traditional ZOE method.
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